Scholarlink

Aims/hypothesis <p>The aim of this study was to identify conserved biomarkers for diabetic retinopathy progression, addressing the lack of minimally invasive biomarkers to track the entire continuum of diabetic retinopathy.</p> Methods <p>We conducted high-throughput proteomics (SomaScan v4.1) on aqueous humour from the Guangdong DR Multiple-Omics Study (<i>n</i>=32). Temporal protein clusters were identified using soft clustering of temporal trajectories. Candidates were validated in a US dataset and localised via single-cell RNA-seq in an oxygen-induced retinopathy mouse model. The clinical relevance of plasma-detectable markers was assessed cross-sectionally and prospectively in individuals with diabetes from the UK Biobank (<i>n</i>=2495).</p> Results <p>In the discovery dataset (mean age 68.5±9.0 years; 56.3% men, 43.8% women), temporal proteomic profiling identified 40 candidate biomarkers whose concentration showed monotonic changes during diabetic retinopathy progression. Of these, 25 showed conserved directional patterns in the validation dataset (17 increasing and eight decreasing, all <i>p</i>&lt;0.05). Single-cell mapping further localised 15 candidates, including neurofilament light chain (NFL), to retinal neurons and glia. In the UK Biobank individuals, baseline plasma NFL distinguished those with diabetic retinopathy from control individuals (OR 1.98 [95% CI 1.61, 2.42]) and predicted incident diabetic retinopathy (HR 2.01 [95% CI 1.48, 2.73]) and vascular complications (microvascular, HR 2.28 [95% CI 1.94, 2.69]; macrovascular, HR 1.49 [95% CI 1.26, 1.77]) over a median follow-up of 12 years. Plasma NFL enhanced the predictability of a conventional risk factor model for diabetic retinopathy (net reclassification improvement [NRI] 0.194 [95% CI 0.042, 0.297]; integrated discrimination improvement [IDI] 0.015 [95% CI 0.003, 0.047]) and enabled risk stratification of vascular complications.</p> Conclusions/interpretation <p>NFL represents a pan-stage biomarker for diabetic retinopathy progression, detectable through minimally invasive plasma testing, and is associated with risks of diabetic vascular complications.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrated intraocular–plasma proteomics reveals conserved biomarkers for diabetic retinopathy progression: a multi-fluid biopsy study

  • 期刊论文

  • 发表日期：

    2026年3月12日

查看全文
  • Jiahui Cao,
  • Fenghao Liu,
  • Huiqian Kong,
  • Chunran Lai,
  • Zijing Du,
  • Zhi Da Soh,
  • Ting Su,
  • Chenxiao Shen,
  • Qinyi Li,
  • Ying Fang,
  • Yijun Hu,
  • Xianwen Shang,
  • Xiaotao Shen,
  • Mingguang He,
  • Ching-Yu Cheng,
  • Zhuoting Zhu,
  • Meijuan Zhou,
  • Xiayin Zhang,
  • Honghua Yu

摘要

Aims/hypothesis

The aim of this study was to identify conserved biomarkers for diabetic retinopathy progression, addressing the lack of minimally invasive biomarkers to track the entire continuum of diabetic retinopathy.

Methods

We conducted high-throughput proteomics (SomaScan v4.1) on aqueous humour from the Guangdong DR Multiple-Omics Study (n=32). Temporal protein clusters were identified using soft clustering of temporal trajectories. Candidates were validated in a US dataset and localised via single-cell RNA-seq in an oxygen-induced retinopathy mouse model. The clinical relevance of plasma-detectable markers was assessed cross-sectionally and prospectively in individuals with diabetes from the UK Biobank (n=2495).

Results

In the discovery dataset (mean age 68.5±9.0 years; 56.3% men, 43.8% women), temporal proteomic profiling identified 40 candidate biomarkers whose concentration showed monotonic changes during diabetic retinopathy progression. Of these, 25 showed conserved directional patterns in the validation dataset (17 increasing and eight decreasing, all p<0.05). Single-cell mapping further localised 15 candidates, including neurofilament light chain (NFL), to retinal neurons and glia. In the UK Biobank individuals, baseline plasma NFL distinguished those with diabetic retinopathy from control individuals (OR 1.98 [95% CI 1.61, 2.42]) and predicted incident diabetic retinopathy (HR 2.01 [95% CI 1.48, 2.73]) and vascular complications (microvascular, HR 2.28 [95% CI 1.94, 2.69]; macrovascular, HR 1.49 [95% CI 1.26, 1.77]) over a median follow-up of 12 years. Plasma NFL enhanced the predictability of a conventional risk factor model for diabetic retinopathy (net reclassification improvement [NRI] 0.194 [95% CI 0.042, 0.297]; integrated discrimination improvement [IDI] 0.015 [95% CI 0.003, 0.047]) and enabled risk stratification of vascular complications.

Conclusions/interpretation

NFL represents a pan-stage biomarker for diabetic retinopathy progression, detectable through minimally invasive plasma testing, and is associated with risks of diabetic vascular complications.

Graphical Abstract